EUCTR2017-004037-93-DK进行中（未招募）1 期
TReat-to-tArget (T2T) with seCukinumab in axial spondyloarthritis. IdEntification of MRI and biochemical biomarkers for disease activity, treatment response and structural damage progression (the TRACE study)
Afdeling for Rygkirurgi, Led- og Bindevævssygdomme ; Rigshospitalet - Glostrup0 个研究点目标入组 88 人开始时间: 2017年11月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Diagnosis of axSpA according to the ASAS criteria and/or AS according to the modified New York criteria as judged by a SpA rheumatologist (regarding imaging in the criteria, see below).
- •2) Active inflammation on MRI of the SIJs and/or spine as evaluated by a central SpA imaging expert and/or radiographic modified New York criteria fulfilled as judged by a central SpA imaging expert.
- •3) Active disease defined as ASDAS = 2.1 (ASDAS high disease activity).
- •4) Total back pain as measured on a VAS scale = 4 0 mm (0-100 mm) at baseline.
- •5) Clinical indication for a biologic drug as assessed by the treating physician.
- •6) Patients should have received at least 2 different NSAIDs at the highest recommended dose for at least 2 weeks each with an inadequate response or failure to respond, or less if therapy had to be reduced due to intolerance, toxicity or contraindications.
- •7) Patients on NSAIDs at inclusion should stay on a stable dose from at least 2 weeks before the baseline MRI scans are performed and to the week 24 visit.
- •8) Patients on sDMARDs (syntetic DMARDs) at inclusion should stay on a stable dose from at least 4 weeks before initiation of secukinumab to the week 24 visit.
- •9) Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must provide written, signed and dated informed consent before any study assessment is performed.
- •10) Male or female patients at least 18 years and less than 70 years of age.
- •11) Sufficient contraception for women.
- •12) Age =18 to <70 years.
- •13) Capable of giving informed consent.
- •14) Capable of complying with the examination programme of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1) Contraindications for secukinumab (described in protocol).
- •2) Contraindication for TNF inhibitor (described in protocol).
- •3) Contraindication for MRI (described in protocol).
- •4) Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor
- •5) Previous exposure to TNF inhibitor or drug targeting TNF.
- •6) Previous exposure to other types of bDMARDs than TNF inhibitor (e.g. anti-interlukin 1, anti-interleukin 6, anti-interleukin 12/23, anti-interleukin 23, anti-CD20, co-stimulation inhibitors, JAK-inhibitors etc).
- •7) Patients taking high-potency opioid analgesics (e.g. methadone, hydromorphone, morphine)
- •8) Any change in the dose of oral corticosteroids in the last 4 weeks prior to the baseline visit or use of i.v. intramuscular or intra-articular corticosteroid during the last 8 weeks prior to the enrollment visit.
- •9) Use of any investigational drug and/or devices within 4 weeks before randomization or a period of 5 half-lives of the investigational drug, whichever is longer.
- •10) Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
- •11) Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g. 20 weeks in EU).
- •12) Known recent drug or alcohol abuse.
- •13) Incapable of complying with the examination programme for physical or mental reasons.
- •14) Failure to provide written consent
研究者
相似试验
招募中
1 期
Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancerCTIS2022-501561-51-00Institut Curie160
已完成
2 期
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab TherapyHER2-Positive Metastatic Breast CancerJPRN-UMIN000012452Chiba Youth Breast Oncology Research Group (CYBORG)35
进行中（未招募）
1 期
Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancerEUCTR2007-004232-22-DKOdense University Hospital
已完成
2 期
Phase II study of TS-1+Irinotecan+Bevacizumab as second-line treatment in patients with metastatic colorectal cancer refractory to fluoronated pyrimidine, oxaliplatin, and cetuximab therapyMetastatic colorectal cancerJPRN-UMIN000010319Japan Clinical Cancer Research Organization70
招募中
2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000012030Saitama Breast Cancer Clinical Study Group30